Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway

Por Momtaz, Parisa, Postow, Michael A
Publicado no Pharmgenomics Pers Med (2014)

Inherited gastrointestinal stromal tumor syndromes: mutations, clinical features, and therapeutic implications

Por Postow, Michael A, Robson, Mark E
Publicado em 2012

Combinations of Radiotherapy and Immunotherapy for Melanoma: A Review of Clinical Outcomes

Por Barker, Christopher A., Postow, Michael A.
Publicado no Int J Radiat Oncol Biol Phys (2014)

Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition

Por Friedman, Claire F., Postow, Michael A.
Publicado no Curr Oncol Rep (2016)

Recent advances in understanding antitumor immunity

Por Munhoz, Rodrigo Ramella, Postow, Michael Andrew
Publicado no F1000Res (2016)

Beyond Cancer Vaccines: A Reason for Future Optimism with Immunomodulatory Therapy

Por Postow, Michael, Callahan, Margaret K., Wolchok, Jedd D.
Publicado em 2011

Targeting Immune Checkpoints: Releasing the Restraints on Anti-tumor Immunity for Patients with Melanoma

Por Postow, Michael A., Harding, James, Wolchok, Jedd D.
Publicado em 2012

Immunomodulatory Therapy for Melanoma: Ipilimumab and Beyond

Por Callahan, Margaret K., Postow, Michael A., Wolchok, Jedd D.
Publicado em 2013

CTLA-4 and PD-1 Pathway Blockade: Combinations in the Clinic

Por Callahan, Margaret K., Postow, Michael A., Wolchok, Jedd D.
Publicado no Front Oncol (2015)

Immune Checkpoint Blockade in Cancer Therapy

Por Postow, Michael A., Callahan, Margaret K., Wolchok, Jedd D.
Publicado no J Clin Oncol (2015)

Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents

Por Weber, Jeffrey S., Postow, Michael, Lao, Christopher D., Schadendorf, Dirk
Publicado no Oncologist (2016)

Radiotherapy and Immune Checkpoint Blockade for Melanoma: A Promising Combinatorial Strategy In Need of Further Investigation

Por Escorcia, Freddy E., Postow, Michael A., Barker, Christopher A.
Publicado no Cancer J (2017)

Ipilimumab in patients with melanoma and autoimmune disease

Por Kyi, Chrisann, Carvajal, Richard D, Wolchok, Jedd D, Postow, Michael A
Publicado em 2014

Checkpoint Modulation in Melanoma: An Update on Ipilimumab and Future Directions

Por Page, David B., Postow, Michael A., Callahan, Margaret K., Wolchok, Jedd D.
Publicado em 2013

Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution

Por Ryder, Mabel, Callahan, Margaret, Postow, Michael A, Wolchok, Jedd, Fagin, James A
Publicado no Endocr Relat Cancer (2014)

Opportunistic infections in patients treated with immunotherapy for cancer

Por Kyi, Chrisann, Hellmann, Matthew D, Wolchok, Jedd D, Chapman, Paul B, Postow, Michael A
Publicado em 2014

Definite regression of cutaneous melanoma metastases upon addition of topical contact sensitizer diphencyprone to immune checkpoint inhibitor treatment

Por Gulati, Nicholas, Carvajal, Richard D., Postow, Michael A., Wolchok, Jedd D., Krueger, James G.
Publicado no Exp Dermatol (2016)

The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma

Por Del Castillo, Maria, Romero, Fabian A., Argüello, Esther, Kyi, Chrisann, Postow, Michael A., Redelman-Sidi, Gil
Publicado no Clin Infect Dis (2016)

T cell receptor diversity evaluation to predict patient response to Ipilimumab in metastatic melanoma

Por Postow, Michael, Manuel, Manuarii, Wong, Phillip, Yuan, Jianda, Noel, Marlene, Courtier, Anais, Pasqual, Nicolas, Wolchok, Jedd D
Publicado no J Immunother Cancer (2014)

Safety of Infusing Ipilimumab Over 30 Minutes

Por Momtaz, Parisa, Park, Vivian, Panageas, Katherine S., Postow, Michael A., Callahan, Margaret, Wolchok, Jedd D., Chapman, Paul B.
Publicado no J Clin Oncol (2015)